Yahoo
NasdaqGM - Delayed Quote USD

Travere Therapeutics, Inc. (TVTX)

65.28 -1.26 (-1.89%)
At close: September 4 at 4:00:00 PM EDT
65.28 0.00 (0.00%)
After hours: September 4 at 7:30:03 PM EDT
Trade TVTX on Coinbase
View in AlphaSpace Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
591,330
490,728
233,175
145,238
109,460
Cost of Revenue
14,078
10,339
7,744
11,450
4,420
Gross Profit
577,252
480,389
225,431
133,788
105,040
Operating Expense
617,710
543,213
546,820
510,532
424,853
Operating Income
-40,458
-62,824
-321,389
-376,744
-319,813
Net Non Operating Interest Income Expense
2,097
1,973
6,635
10,434
-4,738
Other Income Expense
-28,713
11,578
-5,756
-9,800
-6,604
Pretax Income
-67,074
-49,273
-320,510
-376,110
-331,155
Tax Provision
605
988
120
223
313
Net Income Common Stockholders
-43,464
-25,546
-321,545
-111,399
-278,482
Diluted NI Available to Com Stockholders
-43,464
-25,546
-321,545
-111,399
-278,482
Basic EPS
-0.46
-0.29
-4.08
-1.50
-4.37
Diluted EPS
-0.46
-0.29
-4.08
-1.50
-4.37
Basic Average Shares
91,224.89
89,211.81
78,888.86
74,267.42
63,758.52
Diluted Average Shares
91,224.89
89,211.81
78,888.86
74,267.42
63,758.52
Total Operating Income as Reported
-40,458
-62,824
-323,827
-388,138
-319,813
Total Expenses
631,788
553,552
554,564
521,982
429,273
Net Income from Continuing & Discontinued Operation
-43,464
-25,546
-321,545
-111,399
-278,482
Normalized Income
-67,679
-50,261
-318,703.98
-367,331.74
-325,481.38
Interest Income
11,577
12,721
17,817
21,768
6,276
Interest Expense
9,480
10,748
11,182
11,334
11,014
Net Interest Income
2,097
1,973
6,635
10,434
-4,738
EBIT
-57,594
-38,525
-309,328
-364,776
-320,141
EBITDA
5,777
22,218
-265,773
-326,246
-299,422
Reconciled Cost of Revenue
14,078
10,339
7,744
11,450
4,420
Reconciled Depreciation
63,371
60,743
43,555
38,530
20,719
Net Income from Continuing Operation Net Minority Interest
-67,679
-50,261
-320,630
-376,333
-331,468
Total Unusual Items Excluding Goodwill
0
0
-2,438
-11,394
-7,578
Total Unusual Items
0
0
-2,438
-11,394
-7,578
Normalized EBITDA
5,777
22,218
-263,335
-314,852
-291,844
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
-511.98
-2,392.74
-1,591.38
12/31/2022 - 11/8/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: